Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Asthma, Chronic Obstructive Pulmonary Disease
Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)
The purpose of this study is to characterise inspiratory flow parameters across 2 Easyhaler® (EH) inhaler versions and Diskus® inhaler in patients with asthma (including children, adults, and the elderly) and in patients with…
- Trial name
- SALIF (NCT01424137)
- Testing
- Easyhaler type A, Easyhaler type B, Diskus inhaler
- Where
- 5 sites in Estonia, Finland
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.
- Trial name
- iCHOROS (NCT07069829)
- Where
- 36 sites in Argentina, Colombia and 10 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Comparative Effectiveness of COPD Treatments
To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the combination of a long-acting bronchodilators (LABA and the long-acting muscarinic antagonists (LAMA) tiotropium…
- Trial name
- NCT03376295
- Testing
- LABA and the LAMA tiotropium (LABA-TIO), LABA and an ICS (LABA-ICS)
- Where
- Canada
- Volunteers
- 3,954 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and…
- Trial name
- PROSPERO (NCT05742802)
- Testing
- Tozorakimab 1, Tozorakimab 2
- Where
- 335 sites in United States, Argentina and 35 more
- Volunteers
- 1,713 people
- Sponsor
- AstraZeneca
COPD, Chronic Obstructive Pulmonary Disease
The PALP™-COPD Trial (Low-Flow CO2-Removal (ECCO2-R) in Exacerbated COPD)
A Multicenter, Randomized, Controlled Trial to Determine Safety and Efficacy of Pump Assisted Lung Protection (PALP™) for Low Flow Carbon Dioxide (CO2) Removal in Conjunction with Liberation from Mechanical Ventilation Compared…
- Trial name
- PALP-COPD (NCT02107222)
- Testing
- CO2-Removal (PALP-Device/MaquetCP)
- Where
- Germany
- Sponsor
- Maquet Cardiopulmonary GmbH
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase II Study of RC1416 Injection in COPD
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT07402551
- Testing
- RC1416
- Where
- 46 sites in China
- Volunteers
- 180 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the efficacy and safety of two doses of indacaterol in adults aged 40 or over with chronic obstructive pulmonary disease (COPD) in China and in two other countries.
- Trial name
- NCT00792805
- Testing
- Indacaterol 150 µg, Indacaterol 300 μg
- Where
- 15 sites in Australia, China and 1 more
- Volunteers
- 563 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Bronchospasm
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic profiles of A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered…
- Conditions
- Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01189396
- Testing
- A006, Proventil-HFA
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease
Clinical Stabilization of Hypercapnia: NIPPV v HVNI
This study will evaluate the ability of High Velocity Nasal Insufflation [HVNI] to effect ventilation and related physiologic responses in hypercapnic patients when compared to noninvasive positive pressure ventilation [NIPPV].
- Conditions
- Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Dyspnea, Hypercapnic Acidosis
- Trial name
- HYPERACT (NCT04709562)
- Testing
- High Velocity Nasal Insufflation (HVNI), Noninvasive Positive Pressure Ventilation (NIPPV)
- Where
- 7 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Vapotherm, Inc.
Pulmonary Disease, Chronic Obstructive
Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events
Background: Recent observational studies have reported possible arrhythmogenic effects with long-acting beta-agonists (LABA), while the long-acting anticholinergic tiotropium has been associated with cardiovascular and…
- Trial name
- NCT02096731
- Where
- Canada
- Volunteers
- 115,397 people
- Sponsor
- Boehringer Ingelheim
Respiratory Disorders
A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD
The present study aims to assess the natural immunity to specific microbial antigens in healthy subjects and in subjects with stable COPD aged between 45-75 years.
- Trial name
- NCT01516437
- Testing
- Blood collection, Swab collection, Sputum collection
- Where
- 3 sites in Belgium
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)
The purpose of this study is to assess the efficacy (effectiveness) and safety of aclidinium bromide doses as compared to placebo in the treatment of moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT00891462
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 561 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.
- Trial name
- SHINE (NCT01202188)
- Testing
- indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149)
- Where
- 166 sites in United States, Australia and 17 more
- Volunteers
- 2,144 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The objective of this clinical study is to determine the safety of intravenous MN-221 compared to placebo when administered in subjects diagnosed with stable moderate to severe COPD.
- Trial name
- NCT01013142
- Testing
- MN-221 (Dose Group 1), MN-221 (Dose Group 2), MN-221 (Dose Group 3)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- MediciNova
Pulmonary Disease, Chronic Obstructive
Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02233894
- Testing
- Atrovent® - inhalets
- Volunteers
- 526 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)
A clinical study to evaluate the efficacy and safety of MK0633 in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00418613
- Testing
- MK633
- Volunteers
- 266 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To demonstrate that at least one of the two doses of Berodual® (50 µg fenoterol hydrobromide/20 µg ipratropium bromide and 25 µg fenoterol hydrobromide/10 µg ipratropium bromide, 1 puff q.i.d) administered via the Respimat® gives…
- Trial name
- NCT02173782
- Testing
- Berodual® Respimat ® high dose, Berodual® Respimat ® low dose, Berodual® MDI
- Volunteers
- 892 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups.
- Trial name
- AEOLUS (NCT07053423)
- Testing
- Dupilumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)
The purpose of this study is to evaluate the safety, tolerability and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe, stable chronic obstructive pulmonary disease.
- Trial name
- LAS-MD-35 (NCT01044459)
- Testing
- Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg
- Where
- 113 sites in United States, Canada
- Volunteers
- 605 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.